


Complete response to avelumab and IL-15 superagonist N-803 with Abraxane in Merkel cell carcinoma: a case study

Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells

Targeting PD-L1 With Chimeric Antigen Receptor Modified NK Cells Induces Tumor Control and Reduction of PD-L1 High Immune Populations
